ROBO1 Specific CAR-NK Cells(Asclepius Technology)(ROBO1 Specific CAR-NK Cells(Asclepius Technology))

概要

基本信息

药物类型

CAR-NK

别名-

靶点-

作用方式-

作用机制

免疫细胞毒性、自然杀伤细胞替代物

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病

在研适应症-

非在研适应症

胰腺癌

原研机构

阿思科力（苏州）生物科技有限公司

在研机构-

非在研机构

阿思科力（苏州）生物科技有限公司

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

2

项与 ROBO1 Specific CAR-NK Cells(Asclepius Technology) 相关的临床试验

NCT03941457

/ Unknown status临床1/2期

Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer

Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. ROBO1 is a potential target and spectacular paradigm in the treatment of solid tumors. This study is for evaluation of the safety and efficacy of ROBO1 CAR-NK cell immunotherapy for pancreatic cancer.

开始日期2019-05-01

申办/合作机构

阿思科力（苏州）生物科技有限公司

NCT03940820

/ Unknown status临床1/2期

Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors

Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. We have developed anti-ROBO1 CAR-NK cells that can target tumor cells highly expressing ROBO1. The purpose of this study is to evaluate the safety and effectiveness of cell therapy using ROBO1 CAR-NK cells to treat solid tumors.

开始日期2019-05-01

申办/合作机构

阿思科力（苏州）生物科技有限公司

100 项与 ROBO1 Specific CAR-NK Cells(Asclepius Technology) 相关的临床结果

登录后查看更多信息

100 项与 ROBO1 Specific CAR-NK Cells(Asclepius Technology) 相关的转化医学

登录后查看更多信息

100 项与 ROBO1 Specific CAR-NK Cells(Asclepius Technology) 相关的专利（医药）

登录后查看更多信息

100 项与 ROBO1 Specific CAR-NK Cells(Asclepius Technology) 相关的药物交易

登录后查看更多信息